Medical Device Maker Becton Dickinson's Q1 Earnings: Here's Why This Analyst Is Bullish On Long-Term Prospects
Portfolio Pulse from Vandana Singh
Becton, Dickinson and Company (NYSE:BDX) reported Q1 2024 earnings with an adjusted EPS of $2.68, surpassing the consensus of $2.40, but slightly missed revenue expectations with $4.71 billion against a consensus of $4.73 billion. The company's medical and interventional segments saw growth, while life sciences revenue declined. BD raised its fiscal year 2024 revenue and EPS guidance, with William Blair maintaining an Outperform rating due to confidence in BD's long-term margin expansion and achievement of its 2025 goals. BDX shares rose 1.01% to $241.23.
February 01, 2024 | 7:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Becton, Dickinson and Company exceeded Q1 2024 EPS expectations and slightly missed revenue forecasts. The company raised its FY2024 guidance and received a positive outlook from William Blair, leading to a 1.01% increase in its stock price.
BDX's Q1 2024 performance, particularly its EPS beat and raised FY2024 guidance, signals strong financial health and operational efficiency. The positive analyst rating from William Blair further supports investor confidence, contributing to the stock's short-term price increase. The company's progress towards its 2025 goals, especially in margin expansion, underpins its long-term growth prospects, making the news highly relevant and important to investors.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100